title: Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reversal effects of L-prolyl-L-leucyl-glycinamide (PLG).
abstract: Functional supersensitivity of mesolimbic and striatal dopamine receptors has been suggested to contribute to the pathogenesis of schizophrenia and tardive dyskinesia. Using the rodent model of chronic administration of the neuroleptic haloperidol, we investigated the possible desensitizing effects of a tripeptide structurally unrelated to dopamine agonists, L-prolyl-L-leucyl-glycinamide (PLG) on mesolimbic and striatal dopaminergic receptor supersensitivity. Administration of PLG either prior to or after chronic haloperidol, inhibited the supersensitivity of dopamine receptors. The results have implications for pharmacological intervention in preventing tardive dyskinesia and relapse psychosis of schizophrenia.
authors.forename: P
authors.initials: P
authors.lastname: Chiu
authors.forename: G
authors.initials: G
authors.lastname: Rajakumar
authors.forename: S
authors.initials: S
authors.lastname: Chiu
authors.forename: R L
authors.initials: RL
authors.lastname: Johnson
authors.forename: R K
authors.initials: RK
authors.lastname: Mishra
mesh_terms: D000818:Animals; D003342:Corpus Striatum / Q000378:metabolism*; D006220:Haloperidol / Q000494:pharmacology; D007700:Kinetics; D008032:Limbic System / Q000187:drug effects / Q000378:metabolism*; D009075:MSH Release-Inhibiting Hormone / Q000494:pharmacology*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism*; D013134:Spiperone / Q000378:metabolism
chemical_list: D011954:Receptors, Dopamine; D013134:Spiperone; D009075:MSH Release-Inhibiting Hormone; D006220:Haloperidol